Precigen(PGEN) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Precigen Reports First Quarter 2025 Financial Results and Business Updates GERMANTOWN, MD, May 14, 2025 – Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2025 financial results and business updates. "We are extremely pleased with the progress of our PRGN-2012 program and its immense potential for RRP patients. We remain laser-focused on advancing the p ...